[Federal Register: December 18, 2003 (Volume 68, Number 243)]
[Notices]
[Page 70512-70513]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr18de03-53]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Advisory Committee Information Hotline
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that we
have revised the Advisory Committee Information Hotline (the hotline).
The hotline provides the public with access to the most current
information available on FDA advisory committee meetings. This notice
supersedes all previously published announcements of FDA's Advisory
Committee Information Hotline.
FOR FURTHER INFORMATION CONTACT: Theresa L. Green, Committee Management
Officer (HF-4), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-1220.
SUPPLEMENTARY INFORMATION: The Advisory Committee Information Hotline
can be accessed by dialing 1-800-741-8138 or 301-443-0572. The advisory
committee meeting information and information updates can also be
accessed via FDA's Advisory Committee calendar at http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/oc/advisory/accalendar/accalendar.html
.
Each advisory committee is assigned a 10-digit number. This 10-
digit number will appear in each individual notice of meeting. The
public can obtain information about a particular advisory committee
meeting by using the committee's 10-digit number. Information on the
hotline is preliminary and may change before a meeting is actually
held. The hotline will be updated when such changes are made. The
following is a list of each advisory committee's 10-digit number to be
used when accessing the hotline.
------------------------------------------------------------------------
ADVISORY COMMITTEE NUMBER
------------------------------------------------------------------------
OFFICE OF THE COMMISSIONER..............................................
Science Board to the FDA................... 3014512603
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH............................
Allergenic Products Advisory Committee..... 3014512388
Biological Response Modifiers Advisory 3014512389
Committee.
Blood Products Advisory Committee.......... 3014519516
Transmissible Spongiform Encephalopathies 3014512392
Advisory Committee.
Vaccines and Related Biological Products 3014512391
Advisory Committee.
CENTER FOR DRUG EVALUATION AND RESEARCH.................................
Anesthetic and Life Support Drugs Advisory 3014512529
Committee.
Anti-Infective Drugs Advisory Committee 3014512530
(Peds SubC).
Antiviral Drugs Advisory Committee......... 3014512531
Arthritis Advisory Committee............... 3014512532
Cardiovascular and Renal Drugs Advisory 3014512533
Committee.
[[Page 70513]]
Dermatologic and Ophthalmic Drugs Advisory 3014512534
Committee.
Drug Safety and Risk Management Advisory 3014512535
Committee (Drug Abuse Subcommittee).
Endocrinologic and Metabolic Drugs Advisory 3014512536
Committee.
Gastrointestinal Drugs Advisory Committee.. 3014512538
Nonprescription Drugs Advisory Committee... 3014512541
Oncologic Drugs Advisory Committee......... 3014512542
Peripheral and Central Nervous System Drugs 3014512543
Advisory Committee.
Pharmaceutical Science, Advisory Committee 3014512539
for.
Psychopharmacologic Drugs Advisory 3014512544
Committee.
Pulmonary-Allergy Drugs Advisory Committee. 3014512545
Reproductive Health Drugs, Advisory 3014512537
Committee for.
CENTER FOR FOOD SAFETY AND APPLIED NUTRITION............................
Food Advisory Committee (full committee and 3014510564
subcommittees).
Additives and Ingredients Subcommittee .........................
Biotechnology Subcommittee...............
Contaminants and Natural Toxicants
Subcommittee.
Dietary Supplements Subcommittee.........
Infant Formula Subcommittee..............
Nutrition Subcommittee...................
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH..............................
Device Good Manufacturing Practice Advisory 3014512398
Committee.
Medical Devices Advisory Committee N/A
(comprised of 18 panels).
Anesthesiology and Respiratory Therapy 3014512624
Devices Panel.
Circulatory System Devices Panel......... 3014512625
Clinical Chemistry and Clinical 3014512514
Toxicology Devices Panel.
Dental Products Panel.................... 3014512518
Ear, Nose, and Throat Devices Panel...... 3014512522
Gastroenterology-Urology Devices Panel... 3014512523
General and Plastic Surgery Devices Panel 3014512519
General Hospital and Personal Use Devices 3014512520
Panel.
Hematology and Pathology Devices Panel... 3014512515
Immunology Devices Panel................. 3014512516
Medical Devices Dispute Resolution Panel. 3014510232
Microbiology Devices Panel............... 3014512517
Molecular and Clinical Genetics Panel.... 3014510231
Neurological Devices Panel............... 3014512513
Obstetrics-Gynecology Devices............ 3014512524
Ophthalmic Devices Panel................. 3014512396
Orthopaedic and Rehabilitation Devices 3014512521
Panel.
Radiological Devices Panel............... 3014512526
National Mammography Quality Assurance 3014512397
Advisory Committee.
Technical Electronic Product Radiation 3014512399
Safety Standards Committee.
CENTER FOR VETERINARY MEDICINE..........................................
Veterinary Medicine Advisory Committee..... 3014512548
NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH..............................
Science Advisory Board to NCTR............. 3014512559
Advisory Committee on Special Studies 3014512560
Relating to the Possible Long-Term Health
Effects of Phenoxy Herbicides and
Contaminants.
------------------------------------------------------------------------
The hotline will provide the most recent information available on
upcoming advisory committee meetings, guidance for making an oral
presentation during the open public hearing portion of a meeting, and
procedures on obtaining copies of transcripts of advisory committee
meetings. Because the hotline will communicate the most current
information available about any particular advisory committee meeting,
this system will provide interested parties with timely and equal
access to such information. The hotline should also conserve agency
resources by reducing the current volume of inquiries individual FDA
offices and employees must handle concerning advisory committee
schedules and procedures.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.
Dated: December 10, 2003.
Peter J. Pitts,
Associate Commissioner for External Relations.
[FR Doc. 03-31157 Filed 12-17-03; 8:45 am]
BILLING CODE 4160-01-S